A Phase Ib/II Clinical Trial on the Safety and Efficacy of Sirolimus (Albumin-bound) Combined With Different ADCs in Patients With Advanced Solid Tumors
Latest Information Update: 11 Dec 2025
At a glance
- Drugs Sirolimus (Primary) ; CPO 301; CRB 701; DP 303c
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 28 Nov 2025 New trial record